97 research outputs found
Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss.
HER2/neu is a member of the epidermal growth factor receptor family
easily detectable in the serum of cancer patients. We aimed to evaluate
circulating HER-2 concentrations in association with insulin resistance in
healthy and obese subjects. METHODS: Insulin sensitivity (minimal model) and
serum HER-2 concentrations were evaluated in a cross sectional study in men
(cohort 1, n = 167) and longitudinally after weight loss in obese subjects
(cohort 2, n = 30). RESULTS: Serum HER-2 concentrations were positively
associated with BMI and waist circumference (both r = 0.18, p = 0.02), post-load
glucose (r = 0.28, p = 0.001) and fasting triglycerides (r = 0.26, p = 0.001);
and negatively associated with insulin sensitivity (r = -0.29, p = 0.002, n =
109). Subjects with type 2 diabetes showed significantly increased soluble serum
HER-2 concentrations. In different multivariate regression models, fasting
triglycerides emerged as the factor that independently contributed to 10-11% of
serum HER-2 variance.Serum HER-2 concentrations correlated significantly with
fasting triglycerides and insulin sensitivity index in subjects from cohort 2.
Weight loss led to a significant decrease of serum HER-2 concentrations. The
change in serum HER-2 concentrations were significantly associated with the
change in percent body fat and fasting triglycerides in young (below the median
age of the cohort) subjects. CONCLUSIONS: Serum HER-2 concentrations might be
implicated in the pathophysiology of insulin resistance and associated
comorbidities
Circulating omentin concentration increases after weight loss
Omentin-1 is a novel adipokine expressed in visceral adipose tissue
and negatively associated with insulin resistance and obesity. We aimed to study
the effects of weight loss-induced improved insulin sensitivity on circulating
omentin concentrations. METHODS: Circulating omentin-1 (ELISA) concentration in
association with metabolic variables was measured in 35 obese subjects (18 men,
17 women) before and after hypocaloric weight loss. RESULTS: Baseline circulating
omentin-1 concentrations correlated negatively with BMI (r = -0.58, p < 0.001),
body weight (r = -0.35, p = 0.045), fat mass (r = -0.67, p < 0.001), circulating
leptin (r = -0.7, p < 0.001) and fasting insulin (r = -0.37, p = 0.03).
Circulating omentin-1 concentration increased significantly after weight loss
(from 44.9 +/- 9.02 to 53.41 +/- 8.8 ng/ml, p < 0.001). This increase in
circulating omentin after weight loss was associated with improved insulin
sensitivity (negatively associated with HOMA value and fasting insulin, r =
-0.42, p = 0.02 and r = -0.45, p = 0.01, respectively) and decreased BMI (r =
-0.54, p = 0.001). CONCLUSION: As previously described with adiponectin,
circulating omentin-1 concentrations increase after weight loss-induced
improvement of insulin sensitivity
Identification and validation of circulating miRNAs as endogenous controls in obstructive sleep apnea
microRNAs (miRNAs) are non-coding RNAs highly relevant as biomarkers for disease. A seminal study that explored the role of miRNAs in obstructive sleep apnea syndrome (OSA) demonstrated their usefulness in clinical management. Nevertheless, the miRNAs that may act as endogenous controls (ECs) have not yet been established. The identification of ECs would contribute to the standardization of these biomarkers in OSA. The objective of the study is to identify miRNAs that can be used as ECs in OSA. We evaluated 100 patients divided into two different cohorts: a learning cohort of 10 non-OSA and 30 OSA patients, and a validation cohort (20 non-OSA and 40 OSA patients). In the learning cohort, a profile of 188 miRNAs was determined in plasma by TaqMan Low Density Array. The best EC candidates were identified by mean center+SD normalization and concordance correlation restricted normalization. The results were validated using NormFinder and geNorm to assess the stability of those ECs. Eight miRNAs were identified as EC candidates. The combination miRNA-106a/miRNA-186 was identified as the most stable among all candidates. We identified a set of ECs to be used in the determination of circulating miRNA in OSA that may contribute to the homogeneity of results.The project is supported by PI 14/01266 and PI 18/00449 from the Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER), Sociedad Española de Neumología y Cirugía Torácica (SEPAR) and Societat Catalana de Pneumologia (SOCAP). The work is supported by IRBLleida Biobank (B.0000682) and PLATAFORMA BIOBANCOS PT17/0015/0027”. We thank all the investigators of Sleep Unit of Santa Maria Hospital. F.S.-M. is the recipient of a predoctoral fellowship from “AGAUR-University of Lleida” and Convocatòria d’Ajuts 2018 de Promoció a la Recerca en Salut. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Study of caveolin-1 gene expression in whole adipose tissue and its subfractions and during differentiation of human adipocytes
Caveolins are 21-24 kDa integral membrane proteins that serve as
scaffolds to recruit numerous signaling molecules. Specific subclasses of
caveolae carry out specific functions in cell metabolism. In particular,
triglycerides are synthesized at the site of fatty acid entry in one of these
caveolae classes. OBJECTIVE AND METHODS: We studied the expression of caveolin-1
(CAV-1) gene in association with metabolic variables in 90 visceral and 55
subcutaneous adipose tissue samples from subjects with a wide range of fat mass,
in the stromovascular fraction (SVC) and isolated adipocytes, and during
differentiation of human adipocytes. RESULTS: CAV-1 gene expression was
significantly decreased in visceral adipose tissue (v-CAV-1) of obese subjects.
v-CAV-1 was positively associated with several lipogenic genes such as acetyl-coA
carboxylase (ACACA, r = 0.34, p = 0.004) and spot-14 (r = 0.33, p = 0.004). In
non-obese subjects v-CAV-1 also correlated with fatty acid synthase (FAS, r =
0.60, p < 0.0001). Subcutaneous (sc) adipose tissue (sc-CAV-1) gene expression
was not associated with these lipogenic factors when obese and non-obese subjects
were studied together. In obese subjects, however, sc-CAV-1 was associated with
fatty acid synthase (FAS, r = 0.36, p = 0.02), sterol regulatory element binding
protein-1c (SREBP-1c (r = 0.58, p < 0.0001), ACACA (r = 0.33, p = 0.03), spot-14
(r = 0.36, p = 0.02), PPAR-gamma co-activator-1 (PGC-1, r = 0.88, n = 19). In
these obese subjects, sc-CAV-1 was also associated with fasting triglycerides (r
= -0.50, p < 0.0001).CAV-1 expression in mature adipocytes was significantly
higher than in stromal vascular cells. CAV-1 gene expression in adipocytes from
subcutaneous adipose tissue (but not in adipocytes from visceral adipose tissue)
was significatively associated with fasting triglycerides. CAV-1 gene expression
did not change significantly during differentiation of human preadipocytes from
lean or obese subjects despite significant increase of FAS gene expression.
CONCLUSION: Decreased CAV-1 gene expression was simultaneously linked to
increased triglycerides and decreased lipogenic gene expression among obese
subjects, paralleling the observations of hypertriglyceridemia in CAV-1 knockout
mice. However, the regulation of CAV-1 gene expression seems independent of the
adipogenic program
Platelet count and Interleukin 6 Gene polymorphism in healthy subjects
BACKGROUND: Interleukin 6 (IL-6) is thought to play important roles in the development of reactive thrombocytosis caused by inflammation by its stimulatory effect on megakaryocytopoiesis. A G/C polymorphism of the IL-6 gene at position -174 has been found to be associated to different transcription rates. Specifically, subjects with the CC genotype showed lower plasma IL-6 levels compared with GC or GG subjects. Given this difference in transcription rates of IL-6 we speculated on different platelet count according to this IL-6 polymorphism. METHODS: The G/C polymorphism of the IL-6 gene at position -174, serum IL-6 concentration and platelet count were prospectively analyzed in 59 (25 women) consecutive healthy subjects. RESULTS: Subjects who were homozygotes for the C allele at position -174 of the IL-6 gene (Sfa NI genotype) showed significantly lower platelet count than carriers of the G allele, despite similar age, sex, body mass index and proportion of smokers (205400 ± 44088 vs 239818 ± 60194, p = 0.047). This was in parallel to differences in peripheral white blood cell count (5807 ± 1671 vs 6867 ± 1192 × 10(9)/ml, p = 0.01). CONCLUSION: This is the first description, to our knowledge, of a genetical influence on basal platelet counts, which appears to be partially dependent on a polymorphism of the IL-6 gene, even in the absence of inflammation
Natural killer cells act as an extrinsic barrier for <i>in vivo</i> reprogramming
The ectopic expression of transcription factors Oct4, Sox2, Klf4 and Myc (OSKM) enables reprogramming of differentiated cells into pluripotent embryonic stem cells. Methods based on partial and reversible in vivo reprogramming are a promising strategy for tissue regeneration and rejuvenation. However, little is known about the barriers that impair reprogramming in an in vivo context. We report that natural killer (NK) cells significantly limit reprogramming, both in vitro and in vivo. Cells and tissues at the intermediate states of reprogramming upregulate the expression of NK activating ligands, such as MULT1 and ICAM1. NK cells recognize and kill partially reprogrammed cells in a degranulation-dependent manner. Importantly, in vivo partial reprogramming is strongly reduced by adoptive transfer of NK cells, whereas it is significantly improved by depletion of NK cells. Notably, in the absence of NK cells, the pancreatic organoids derived from OSKM-expressing mice are remarkably large, suggesting the generation of cells with progenitor properties. We conclude that NK cells pose an important barrier for in vivo reprogramming, and this concept may apply to other contexts of transient cellular plasticity
Decreased TLR3 in Hyperplastic Adipose Tissue, Blood and Inflamed Adipocytes is Related to Metabolic Inflammation
Background/Aims: Obesity is characterized by the immune activation that eventually dampens insulin sensitivity and changes metabolism. This study explores the impact of different inflammatory/ anti-inflammatory paradigms on the expression of toll-like receptors (TLR) found in adipocyte cultures, adipose tissue, and blood. Methods: We evaluated by real time PCR the impact of acute surgery stress in vivo (adipose tissue) and macrophages (MCM) in vitro (adipocytes). Weight loss was chosen as an anti-inflammatory model, so TLR were analyzed in fat samples collected before and after bariatric surgery-induced weight loss. Associations with inflammatory and metabolic parameters were analyzed in non-obese and obese subjects, in parallel with gene expression measures taken in blood and isolated adipocytes/ stromal-vascular cells (SVC). Treatments with an agonist of TLR3 were conducted in human adipocyte cultures under normal conditions and upon conditions that simulated the chronic low-grade inflammatory state of obesity. Results: Surgery stress raised TLR1 and TLR8 in subcutaneous (SAT), and TLR2 in SAT and visceral (VAT) adipose tissue, while decreasing VAT TLR3 and TLR4. MCM led to increased TLR2 and diminished TLR3, TLR4, and TLR5 expressions in human adipocytes. The anti-inflammatory impact of weight loss was concomitant with decreased TLR1, TLR3, and TLR8 in SAT. Cross-sectional associations confirmed increased V/ SAT TLR1 and TLR8, and decreased TLR3 in obese patients, as compared with non-obese subjects. As expected, TLR were predominant in SVC and adipocyte precursor cells, even though expression of all of them but TLR8 (very low levels) was also found in ex vivo isolated and in vitro differentiated adipocytes. Among SVC, CD14+ macrophages showed increased TLR1, TLR2, and TLR7, but decreased TLR3 mRNA. The opposite patterns shown for TLR2 and TLR3 in V/ SAT, SVC, and inflamed adipocytes were observed in blood as well, being TLR3 more likely linked to lymphocyte instead of neutrophil counts. On the other hand, decreased TLR3 in adipocytes challenged with MCM dampened lipogenesis and the inflammatory response to Poly(I:C). Conclusion: Functional variations in the expression of TLR found in blood and hypertrophied fat depots, namely decreased TLR3 in lymphocytes and inflamed adipocytes, are linked to metabolic inflammation
Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations
Fibroblast growth factor 23 (FGF-23) is known to be produced by the bone and linked to metabolic risk. We aimed to
explore circulating FGF-23 in association with fatness and insulin sensitivity, atherosclerosis and bone mineral density
(BMD). Circulating intact FGF-23 (iFGF-23) and C-terminal (CtFGF-23) concentrations (ELISA) were measured in 133 middle
aged men from the general population in association with insulin sensitivity (Cohort 1); and in association with fat mass and
bone mineral density (DEXA) and atherosclerosis (intima media thickness, IMT) in 78 subjects (52 women) with a wide range
of adiposity (Cohort 2). Circulating iFGF-23 was also measured before and after weight loss. In all subjects as a whole, serum
intact and C-terminal concentrations were linearly and positively associated with BMI. In cohort 1, both serum iFGF-23 and
CtFGF-23 concentrations increased with insulin resistance. Serum creatinine contributed to iFGF-23 variance, while serum
ferritin and insulin sensitivity (but not BMI, age or serum creatinine) contributed to 17% of CtFGF-23 variance. In cohort 2,
CtFGF-23 levels were higher in women vs. men, and increased with BMI, fat mass, fasting and post-load serum glucose,
insulin, HOMA-IR and PTH, being negatively associated with circulating vitamin D and ferritin levels. The associations of
CtFGF-23 with bone density in the radius, lumbar spine and carotid IMT were no longer significant after controlling for BMI.
Weight loss led to decreased iFGF-23 concentrations. In summary, the associations of circulating FGF-23 concentration with
parameters of glucose metabolism, bone density and atherosclerosis are dependent on iron and obesity status-associated
insulin resistance
- …